Treatment of Genital Warts
Treatment should be initiated with either patient-applied podofilox 0.5% solution/gel or imiquimod 5% cream for most patients, or provider-administered cryotherapy with liquid nitrogen for those preferring office-based therapy. 1
Treatment Selection Algorithm
Patient-Applied Options (First-Line)
Podofilox 0.5% solution or gel:
- Apply twice daily for 3 consecutive days, followed by 4 days off therapy 1
- Repeat cycle up to 4 times (maximum 4 weeks total) 1
- Treat area must not exceed 10 cm² and volume limited to 0.5 mL per day 1
- Provider should demonstrate initial application technique 1
- Most effective patient-applied therapy for wart clearance 2
- Contraindicated in pregnancy 1
Imiquimod 5% cream:
- Apply once daily at bedtime, 3 times per week (e.g., Monday/Wednesday/Friday) for up to 16 weeks 1, 3
- Wash treatment area with mild soap and water 6-10 hours after application 1, 3
- Achieves 50% complete clearance in immunocompetent patients 4
- In clinical trials: 50% clearance rate overall, 72% in females, 33% in males 3
- Median time to complete clearance is 10 weeks 3
- Contraindicated in pregnancy 1, 2
Provider-Administered Options (First-Line)
Cryotherapy with liquid nitrogen:
- Apply every 1-2 weeks until clearance 1, 5
- Efficacy 63-88% with recurrence rates 21-39% 5, 4
- Does not require anesthesia 5
- Safe in pregnancy 5, 4
- Most accessible first-line destructive treatment 6
Trichloroacetic acid (TCA) 80-90%:
- Apply small amount only to warts until white "frosting" develops 1, 5
- Neutralize excess acid immediately with talc, sodium bicarbonate, or liquid soap 1, 5
- Repeat weekly for maximum 6 applications 5
- Efficacy 81% with 36% recurrence rate 5, 4
- Safe in pregnancy 5, 4
Podophyllin resin 10-25%:
- Apply to each wart, allow to air dry, repeat weekly 1
- Limit to <0.5 mL or <10 cm² per session to avoid systemic toxicity 1
- Wash off thoroughly 1-4 hours after application 1
- Contraindicated in pregnancy 1
Surgical Options (Reserved for Treatment Failures or Extensive Disease)
Surgical removal:
- Tangential scissor excision, shave excision, curettage, or electrosurgery 1
- Efficacy 93% with 29% recurrence rate 5, 4
- Most effective for wart removal at end of treatment 2
- Reserved for extensive disease or after 6 failed treatments 1
CO2 laser therapy:
- Alternative for extensive or refractory warts 7, 6
- Recurrence rate approximately 28-30% within 3 months to 3 years 7
- Reserved for treatment failures, not first-line 7
Critical Treatment Principles
When to change treatment modality:
- Switch if no substantial improvement after 3 provider-administered treatments 1
- Switch if warts not completely cleared after 6 treatments 1
- Avoid overtreatment by continuously evaluating risk-benefit ratio 1
Natural history considerations:
- 20-30% of genital warts clear spontaneously within 3 months without treatment 5, 4
- Observation without treatment is acceptable for some patients 1
- Treatment removes visible warts but does not eradicate HPV virus 5, 4
- Recurrence is common (approximately 30%) regardless of treatment method 5, 7, 4
Anatomic considerations:
- Warts on moist surfaces and intertriginous areas respond better to topical treatments 1
- Warts on drier surfaces respond better to ablative therapies 1
- External anal warts can be treated in primary care; intra-anal warts require specialist referral 5, 4
Special Population Considerations
Pregnancy:
HIV-positive/immunocompromised patients:
Common Pitfalls and Complications
Scarring and pigmentation changes:
- Persistent hypopigmentation or hyperpigmentation common with ablative modalities 1
- Depressed or hypertrophic scars uncommon but occur with insufficient healing time between treatments 1
Chronic pain syndromes:
- Rarely, treatment can cause disabling chronic pain (vulvodynia, hyperesthesia) 1
Local skin reactions:
- Expected with imiquimod (erythema, erosion, excoriation, edema) 3
- Rest period of several days acceptable if reactions severe 3
- Systemic flu-like symptoms may occur with imiquimod 3
Treatment area restrictions: